ELIQUIS® (apixaban) receives positive opinion from CHMP
24 September 2012 | By Pfizer
For the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation...
List view / Grid view
24 September 2012 | By Pfizer
For the prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation...
19 September 2012 | By Bristol-Myers Squibb
New non-profit organization to speed pharmaceutical R&D...
17 September 2012 | By Pfizer
14 abstracts for tofacitinib...
12 September 2012 | By Pfizer
Pfizer Inc. and Zhejiang Hisun Pharmaceuticals announced the launch of Hisun-Pfizer Pharmaceuticals Co., Ltd...
11 September 2012 | By Pfizer
WHO has granted an expansion to the prequalification for Prevenar 13...
4 September 2012 | By Pfizer
The European Commission has granted marketing authorization for INLYTA® (axitinib)...
4 September 2012 | By Pfizer
“BOSULIF is the third new medicine to be approved by the FDA in just 13 months..."
In this Informatics In-Depth Focus: Developing Informatics for the pharmaceutical industry; Rolling out a biology ELN at UCB Pharma; Ask the Informatics experts; Laboratory Informatics – Out of the fog and into the cloud?
21 August 2012 | By Pfizer
The U.S. FDA has extended the action date by three months for the NDA for tofacitinib...
13 August 2012 | By AstraZeneca
NEXIUM 20mg retail launch targeted for 2014, subject to regulatory approval...
10 August 2012 | By Pfizer
Pfizer Inc. announced the Phase 3 INTORACT trial (B1771006) did not meet its primary endpoint...
9 August 2012 | By Pfizer
Nodality, Inc.has announced a strategic collaboration with Pfizer Inc..
8 August 2012 | By Pfizer
Company reaches five-year public goal a year earlier than anticipated...
7 August 2012 | By Pfizer
U.S. agencies praise company’s cooperation and compliance program...
6 August 2012 | By Pfizer
Bapineuzumab IV Phase 3 program discontinued...